

FORM PTO-1449
(Rev. 2-32)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.

07-1009-WO-US

Serial No.

10/580,164

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

Applicant:
Mark Ian Christie

Filing Date:
May 18, 2006

Group:
1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/P.M./	6,274,711	08/14/01	Golstein, et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Kotake, et al., <i>IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis</i> , The Journal of Clinical Investigation, 103:1345-1352 (1999).
	Chabaud, et al., <i>Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis</i> , Cytokine, 12:1092-1099 (2000).
EXAMINER	/Prema Mertz/

DATE CONSIDERED

06/17/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.